CA2648330C - Anti-ccr2 antibody depletes monocytes to treat multiple sclerosis and rheumatoid arthritis - Google Patents

Anti-ccr2 antibody depletes monocytes to treat multiple sclerosis and rheumatoid arthritis Download PDF

Info

Publication number
CA2648330C
CA2648330C CA2648330A CA2648330A CA2648330C CA 2648330 C CA2648330 C CA 2648330C CA 2648330 A CA2648330 A CA 2648330A CA 2648330 A CA2648330 A CA 2648330A CA 2648330 C CA2648330 C CA 2648330C
Authority
CA
Canada
Prior art keywords
antibody
ccr2
monocytes
human
multiple sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2648330A
Other languages
English (en)
French (fr)
Other versions
CA2648330A1 (en
Inventor
Marco Prinz
Wolfgang Brueck
Alexander Mildner
Matthias Mack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaetsmedizin Goettingen Georg August Universitaet
Universitätsklinikum Regensburg
Original Assignee
Universitaetsmedizin Goettingen Georg August Universitaet
Universitätsklinikum Regensburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaetsmedizin Goettingen Georg August Universitaet, Universitätsklinikum Regensburg filed Critical Universitaetsmedizin Goettingen Georg August Universitaet
Publication of CA2648330A1 publication Critical patent/CA2648330A1/en
Application granted granted Critical
Publication of CA2648330C publication Critical patent/CA2648330C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2648330A 2006-04-03 2007-04-02 Anti-ccr2 antibody depletes monocytes to treat multiple sclerosis and rheumatoid arthritis Expired - Fee Related CA2648330C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006015341.3 2006-04-03
DE102006015341A DE102006015341A1 (de) 2006-04-03 2006-04-03 Behandlung von multipler Sklerose und/oder rheumatoider Arthritis
PCT/EP2007/002929 WO2007115713A1 (de) 2006-04-03 2007-04-02 Behandlung von multipler sklerose und/oder rheumatoider arthritis

Publications (2)

Publication Number Publication Date
CA2648330A1 CA2648330A1 (en) 2007-10-18
CA2648330C true CA2648330C (en) 2015-11-24

Family

ID=38226352

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2648330A Expired - Fee Related CA2648330C (en) 2006-04-03 2007-04-02 Anti-ccr2 antibody depletes monocytes to treat multiple sclerosis and rheumatoid arthritis

Country Status (8)

Country Link
US (1) US9068002B2 (enExample)
EP (2) EP2481757A1 (enExample)
JP (1) JP2009532399A (enExample)
CN (1) CN101466735A (enExample)
AU (1) AU2007236269B2 (enExample)
CA (1) CA2648330C (enExample)
DE (1) DE102006015341A1 (enExample)
WO (1) WO2007115713A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013276994C1 (en) * 2007-08-13 2016-08-11 Takeda Pharmaceutical Company Limited IVIG Modulations of Chemokines for Treatment of Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease
EP2727944A1 (en) * 2012-10-30 2014-05-07 Universitätsklinikum Regensburg Depletion of CCR2-positive monocytes for the treatment of inflammatory conditions in the gastrointestinal system
EP3612563A1 (en) * 2017-04-19 2020-02-26 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
WO2020232127A1 (en) * 2019-05-13 2020-11-19 The Research Foundation For The State University Of New York Compositions and methods to block and bind ccr2 to modulate cellular function
JP7397996B2 (ja) 2020-11-09 2023-12-13 武田薬品工業株式会社 抗体薬物コンジュゲート
WO2023072916A1 (en) 2021-10-27 2023-05-04 Granite Bio Ag Antibodies targeting ccr2
CN121399160A (zh) 2023-05-29 2026-01-23 花岗岩生物股份公司 靶向ccr2的抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SE9600820D0 (sv) 1996-03-01 1996-03-01 Pharmacia Ab Antibodies and their use
US6696550B2 (en) * 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US6312689B1 (en) * 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6723538B2 (en) * 1999-03-11 2004-04-20 Micromet Ag Bispecific antibody and chemokine receptor constructs
AU2001233277B2 (en) 2000-02-03 2004-06-03 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use therefor
SE0002045D0 (sv) 2000-05-31 2000-05-31 Sahltech Ab New use
US20040151721A1 (en) 2001-10-19 2004-08-05 O'keefe Theresa Humanized anti-CCR2 antibodies and methods of use therefor
WO2005060368A2 (en) * 2003-12-10 2005-07-07 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use

Also Published As

Publication number Publication date
EP2004692B1 (de) 2013-07-24
AU2007236269A1 (en) 2007-10-18
US9068002B2 (en) 2015-06-30
AU2007236269B2 (en) 2012-09-20
CN101466735A (zh) 2009-06-24
US20090311273A1 (en) 2009-12-17
WO2007115713A1 (de) 2007-10-18
CA2648330A1 (en) 2007-10-18
JP2009532399A (ja) 2009-09-10
EP2481757A1 (de) 2012-08-01
EP2004692A1 (de) 2008-12-24
DE102006015341A1 (de) 2007-10-04

Similar Documents

Publication Publication Date Title
Sitaru et al. Mechanisms of blister induction by autoantibodies
Christensen et al. K/BxN serum-transfer arthritis as a model for human inflammatory arthritis
JP5693127B2 (ja) Ｎｋｇ２ｄの調節
Brühl et al. Targeting of Gr‐1+, CCR2+ monocytes in collagen‐induced arthritis
JP7015820B2 (ja) 薬物としての使用のための抗ｃｄ４５ｒｃ抗体
AU2007236269B2 (en) Treatment of multiple sclerosis and/or rheumatoid arthritis
JP2024026724A (ja) 抗ｃｘｃｒ２抗体及びその使用
JPH08505365A (ja) 自己免疫疾患および炎症性疾患の治療
JP2009543579A (ja) 抗炎症反応のための標的としてのＷＳＸ−１／ｐ２８
JP5777522B2 (ja) 初期段階の関節リウマチ治療用のｉｌ−３阻害剤
CN112451661A (zh) α-烯醇化酶特异性抗体及其在免疫疾病治疗中的使用方法
US20080248025A1 (en) Gamma Delta T Cells and Methods of Treatment of Interleukin-17 Related Conditions
TWI879859B (zh) 急性期之視神經脊髓炎之預防或治療劑
US20110142857A1 (en) Methods of altering peripheral b cell populations and uses thereof
US11702470B2 (en) Use of CXCL13 binding molecules to promote peripheral nerve regeneration
JP2022500387A (ja) Ｍｕｓｋ阻害
Ochs Proinflammatory CD20+ T cells: Their origin and therapeutic depletion in CNS-directed autoimmunity
Soulillou et al. Monoclonal anti‐IL2‐receptor in organ transplantation
DeVoss The role of classical allergy-related genes in experimental autoimmune encephalomyelitis, an animal model for multiple sclerosis
Denney Enzymatic cleavage of chemokines CCL2 and CXCL10: Implications for multiple sclerosis pathogenesis

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190402